Kaposi sarcoma

C3_KAPOSI_SARCOMA

Kaposi's sarcoma: A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Hospital Discharge: ICD-10 C46

Hospital discharge: ICD-9 $!$

Hospital discharge: ICD-8 $!$

Cause of death: ICD-10 C46

Cause of death: ICD-9 $!$

Cause of death: ICD-8 $!$

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

Check minimum number of events None

Include endpoints None

C3_KAPOSI_SARCOMA

Extra metadata

Level in the ICD hierarchy 3

First used in FinnGen datafreeze DF4

Parent code in ICD-10 C45-C49

Name in latin Sarcoma Kaposi

Similar endpoints

↥

List of similar endpoints to Kaposi sarcoma based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	27	7	20
Unadjusted prevalence (%)	0.01	0.00	0.01
Mean age at first event (years)	63.26	63.99	63.00

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: C3_KAPOSI_SARCOMA – Kaposi sarcoma
GWS hits:

Survival analyses between endpoints

↥

Plot

before Kaposi sarcoma
after Kaposi sarcoma

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Kaposi sarcoma

↥